In the EZH2 higher‐expressed group, no significant differences in OS and LFS were found between HSCT and chemotherapy groups among both whole‐cohort AML and non‐M3‐AML (Figure 4). The gene discussed is EZH2; the disease is acute myeloid leukemia.